Compare DAIO & GNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAIO | GNTA |
|---|---|---|
| Founded | 1969 | 2014 |
| Country | United States | Italy |
| Employees | N/A | 13 |
| Industry | Electrical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.9M | 19.9M |
| IPO Year | 1995 | N/A |
| Metric | DAIO | GNTA |
|---|---|---|
| Price | $3.92 | $1.79 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $5.22 | N/A |
| AVG Volume (30 Days) | 144.5K | ★ 2.0M |
| Earning Date | 05-14-2026 | 03-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $21,500,000.00 | N/A |
| Revenue This Year | $4.51 | N/A |
| Revenue Next Year | $30.29 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.16 | $0.55 |
| 52 Week High | $4.49 | $10.00 |
| Indicator | DAIO | GNTA |
|---|---|---|
| Relative Strength Index (RSI) | 59.81 | 60.01 |
| Support Level | $2.89 | $1.31 |
| Resistance Level | $4.10 | $2.20 |
| Average True Range (ATR) | 0.28 | 0.26 |
| MACD | -0.05 | -0.02 |
| Stochastic Oscillator | 68.91 | 47.96 |
Data I/O Corp provides semiconductor programming, security provisioning, and intellectual property protection and management solutions used in electronics manufacturing with flash memory, microcontrollers, and flash memory-based intelligent devices as well as secure element devices, authentication devices and secure microcontrollers. It operates as a single segment entity, with the sole objective to design, manufacture, and sell programming solutions and Programming-as-a-Service (PaaS) to the world's various electronics manufacturers including OEMs, CMs and EMS companies. The company operate in three separate locations Redmond, Washington; Shanghai, China; and Munich, Germany.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.